These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22659483)

  • 21. Measuring dopamine neuromodulation in the thalamus: using [F-18]fallypride PET to study dopamine release during a spatial attention task.
    Christian BT; Lehrer DS; Shi B; Narayanan TK; Strohmeyer PS; Buchsbaum MS; Mantil JC
    Neuroimage; 2006 May; 31(1):139-52. PubMed ID: 16469510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endogenous competition against binding of [(18)F]DMFP and [(18)F]fallypride to dopamine D(2/3) receptors in brain of living mouse.
    Rominger A; Wagner E; Mille E; Böning G; Esmaeilzadeh M; Wängler B; Gildehaus FJ; Nowak S; Bruche A; Tatsch K; Bartenstein P; Cumming P
    Synapse; 2010 Apr; 64(4):313-22. PubMed ID: 19957365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measurement of d-amphetamine-induced effects on the binding of dopamine D-2/D-3 receptor radioligand, 18F-fallypride in extrastriatal brain regions in non-human primates using PET.
    Mukherjee J; Christian BT; Narayanan TK; Shi B; Collins D
    Brain Res; 2005 Jan; 1032(1-2):77-84. PubMed ID: 15680944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative PET analysis of the dopamine D2 receptor agonist radioligand 11C-(R)-2-CH3O-N-n-propylnorapomorphine in the human brain.
    Otsuka T; Ito H; Halldin C; Takahashi H; Takano H; Arakawa R; Okumura M; Kodaka F; Miyoshi M; Sekine M; Seki C; Nakao R; Suzuki K; Finnema S; Hirayasu Y; Suhara T; Farde L
    J Nucl Med; 2009 May; 50(5):703-10. PubMed ID: 19372485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [18F]Fallypride PET measurement of striatal and extrastriatal dopamine D 2/3 receptor availability in recently abstinent alcoholics.
    Rominger A; Cumming P; Xiong G; Koller G; Böning G; Wulff M; Zwergal A; Förster S; Reilhac A; Munk O; Soyka M; Wängler B; Bartenstein P; la Fougère C; Pogarell O
    Addict Biol; 2012 Mar; 17(2):490-503. PubMed ID: 22023291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PET radiotracer development for imaging high-affinity state of dopamine D2 and D3 receptors: Binding studies of fluorine-18 labeled aminotetralins in rodents.
    Mukherjee J; Majji D; Kaur J; Constantinescu CC; Narayanan TK; Shi B; Nour MT; Pan ML
    Synapse; 2017 Mar; 71(3):. PubMed ID: 27864853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia.
    Buchsbaum MS; Christian BT; Lehrer DS; Narayanan TK; Shi B; Mantil J; Kemether E; Oakes TR; Mukherjee J
    Schizophr Res; 2006 Jul; 85(1-3):232-44. PubMed ID: 16713185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PET imaging of brain 5-HT1A receptors in rat in vivo with 18F-FCWAY and improvement by successful inhibition of radioligand defluorination with miconazole.
    Tipre DN; Zoghbi SS; Liow JS; Green MV; Seidel J; Ichise M; Innis RB; Pike VW
    J Nucl Med; 2006 Feb; 47(2):345-53. PubMed ID: 16455642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small effect of dopamine release and no effect of dopamine depletion on [18F]fallypride binding in healthy humans.
    Cropley VL; Innis RB; Nathan PJ; Brown AK; Sangare JL; Lerner A; Ryu YH; Sprague KE; Pike VW; Fujita M
    Synapse; 2008 Jun; 62(6):399-408. PubMed ID: 18361438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual-radiotracer translational SPECT neuroimaging. Comparison of three methods for the simultaneous brain imaging of D
    Tsartsalis S; Tournier BB; Habiby S; Ben Hamadi M; Barca C; Ginovart N; Millet P
    Neuroimage; 2018 Aug; 176():528-540. PubMed ID: 29723640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo measurement of the affinity and density of metabotropic glutamate receptor subtype 1 in rat brain using 18F-FITM in small-animal PET.
    Yamasaki T; Fujinaga M; Kawamura K; Yui J; Hatori A; Ohya T; Xie L; Wakizaka H; Yoshida Y; Fukumura T; Zhang MR
    J Nucl Med; 2012 Oct; 53(10):1601-7. PubMed ID: 22915159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of an extracerebral reference region approach for the quantification of brain nicotinic acetylcholine receptors in squirrel monkeys with PET and 2-18F-fluoro-A-85380.
    Le Foll B; Chefer SI; Kimes AS; Shumway D; Goldberg SR; Stein EA; Mukhin AG
    J Nucl Med; 2007 Sep; 48(9):1492-500. PubMed ID: 17704243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alteration of dopamine D2/D3 receptor binding in patients with juvenile myoclonic epilepsy.
    Landvogt C; Buchholz HG; Bernedo V; Schreckenberger M; Werhahn KJ
    Epilepsia; 2010 Sep; 51(9):1699-706. PubMed ID: 20384765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased dopamine D2/D3-receptor binding in temporal lobe epilepsy: an [18F]fallypride PET study.
    Werhahn KJ; Landvogt C; Klimpe S; Buchholz HG; Yakushev I; Siessmeier T; Müller-Forell W; Piel M; Rösch F; Glaser M; Schreckenberger M; Bartenstein P
    Epilepsia; 2006 Aug; 47(8):1392-6. PubMed ID: 16922886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-in-human PET quantification study of cerebral α4β2* nicotinic acetylcholine receptors using the novel specific radioligand (-)-[(18)F]Flubatine.
    Sabri O; Becker GA; Meyer PM; Hesse S; Wilke S; Graef S; Patt M; Luthardt J; Wagenknecht G; Hoepping A; Smits R; Franke A; Sattler B; Habermann B; Neuhaus P; Fischer S; Tiepolt S; Deuther-Conrad W; Barthel H; Schönknecht P; Brust P
    Neuroimage; 2015 Sep; 118():199-208. PubMed ID: 26037057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [
    Mann T; Kurth J; Hawlitschka A; Stenzel J; Lindner T; Polei S; Hohn A; Krause BJ; Wree A
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29509680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantification of PET studies with the very high-affinity dopamine D2/D3 receptor ligand [11C]FLB 457: re-evaluation of the validity of using a cerebellar reference region.
    Asselin MC; Montgomery AJ; Grasby PM; Hume SP
    J Cereb Blood Flow Metab; 2007 Feb; 27(2):378-92. PubMed ID: 16736043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study.
    Gründer G; Fellows C; Janouschek H; Veselinovic T; Boy C; Bröcheler A; Kirschbaum KM; Hellmann S; Spreckelmeyer KM; Hiemke C; Rösch F; Schaefer WM; Vernaleken I
    Am J Psychiatry; 2008 Aug; 165(8):988-95. PubMed ID: 18381901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and evaluation in rats of the dopamine D2/3 receptor agonist 18F-AMC20 as a potential radioligand for PET.
    Shalgunov V; van Wieringen JP; Janssen HM; Fransen PM; Dierckx RA; Michel MC; Booij J; Elsinga PH
    J Nucl Med; 2015 Jan; 56(1):133-9. PubMed ID: 25476538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride.
    Narendran R; Frankle WG; Mason NS; Rabiner EA; Gunn RN; Searle GE; Vora S; Litschge M; Kendro S; Cooper TB; Mathis CA; Laruelle M
    Synapse; 2009 Jun; 63(6):447-61. PubMed ID: 19217025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.